Heart failure affects 4% of the US population, yet treatment options are primarily symptomatic, including blood thinners, assistive devices and heart transplant. Patients today face a 50% 5-year survival rate upon diagnosis. It’s time to change that. Our approach is to engineer human cardiac organoids that function similarly to adult human heart tissue, enabling us to directly target therapeutics to the heart. We aim to address the root cause of heart failure and restore heart function.